Axelia Oncology

Executive Summary

Axelia Oncology is an Australian biopharmaceutical company developing systemic TLR2/6 agonists to activate the innate immune system against solid tumors that are resistant to checkpoint blockade. Its lead candidate, AXA-042, leverages vaccine adjuvant research from the Peter Doherty Institute to reprogram the tumor microenvironment and enhance anti-tumor immunity. The company's approach addresses a critical unmet need in immuno-oncology, particularly for patients who do not respond to existing immunotherapies. Founded in 2020 and based in Melbourne, Axelia has raised approximately $10 million to advance its preclinical and Phase 1 programs. Currently, Axelia is conducting a first-in-human Phase 1 clinical trial evaluating AXA-042 as a monotherapy and in combination with checkpoint inhibitors. Early safety and pharmacodynamic data are expected to provide proof-of-mechanism and guide dose selection for subsequent trials. With a novel mode of action targeting innate immunity, Axelia's technology has the potential to broaden the responsive patient population. However, the company remains at an early stage, and successful clinical proof-of-concept is required to justify further investment. Key upcoming milestones include initial data readouts and potential partnership discussions to support continued development.

Upcoming Catalysts (preview)

• H2 2026Initial Phase 1 safety and biomarker data release70% success
• H1 2026Presentation of preclinical combination data at a major oncology conference60% success
• TBDPotential strategic partnership for ex-Australia development rights30% success